Elligo Health Research, a Texas-based research organization emphasizing models supporting clinical research-as-a-care-option, has inked an alliance with health data specialists Verily (part of Google) to support the Project Baseline COVID-19 initiative. In collaboration with Gov. Gavin Newsome’s office, in addition to numerous public health authorities in the Golden State, the team seeks to considerably expand COVID-19 testing and risk screening. In following the model of other nations such as Taiwan, wide-scale testing, contact tracing and data transparency paves the way to a more stable and certain path forward.
Leveraging an ongoing Initiative
The parties sought to leverage Verily’s Project Baseline, launched in 2017, which sought to bridge the gap between clinical research and clinical care. Due to the significant data collection and secure health information storage options, it made sense to embrace the existing efforts for expanding COVID-19 testing in the state. Last month, the team kicked off a pilot program testing high-risk individuals at select San Francisco Bay Area sites: samples were collected in San Mateo and Santa Clara counties with more locations to open soon, reported Elligo.
Focusing on the Hardest-Hit Communities
According to a report by Jenni Spinner of Outsourcing-Pharma, Elligo is helping the group focus on supporting individuals and communities most impacted by the pandemic while working diligently to produce more data and ultimately knowledge about the novel coronavirus.
Planning for the Next Crisis
Chad Moore, President of Elligo, noted to Ms. Spinner that clinical sponsors must prepare for future crisis-driven disruptions, noting: “As existing studies are attended to, the industry is beginning to determine how best to prepare for the next pandemic so the impact on patients and studies is minimized,” he told us. “We’ve talked to many current and prospective sponsor and CRO customers; most intend to meaningfully accelerate the incorporation of eSource data collection, remote monitoring, decentralized study design, site-fewer patient visits, and generally making it easier for patients to participate in research.”